Skip to main content
Biocartis Group NV logo

Biocartis Group NV — Investor Relations & Filings

Ticker · BCART ISIN · BE0974281132 LEI · 549300J4HOJL5KG8HY54 BR Manufacturing
Open in API
Filings indexed 636 across all filing types
Latest filing 2017-09-21 Director's Dealing
Country BE Belgium
Listing BR BCART

About Biocartis Group NV

https://www.biocartis.com/en

Biocartis Group NV is a molecular diagnostics company that develops and commercializes its proprietary Idylla™ platform. This fully automated, sample-to-result system is designed to provide fast, easy, and actionable molecular diagnostic results, making advanced testing accessible to laboratories of any size. The company's primary focus is in the field of oncology, offering a menu of tests that support the diagnosis and treatment of various cancers, including lung, colorectal, melanoma, and breast cancer. Biocartis aims to enable personalized medicine for patients by providing universal access to molecular testing. The company also collaborates with pharmaceutical partners in the development of companion diagnostics.

Recent filings

Filing Released Lang Actions
170920 Transp notif Capfi Delen Asset Mgt_5_ENG_FINAL.pdf
Director's Dealing Classification · 98% confidence The document is explicitly titled as a 'PRESS RELEASE REGULATED INFORMATION' and announces the 'Disclosure of a transparency notification' regarding a change in major shareholdings (Capfi Delen Asset Management NV crossing the 5% threshold). This directly relates to reporting changes in significant ownership, which corresponds to the Major Shareholding Notification category (MRQ). Although it is a press release, the core content is the notification itself, not just the announcement of a report's publication (RPA) or a general regulatory filing (RNS).
2017-09-21 English
170920 Transp notif Capfi Delen Asset Mgt_5_NL_FINAL.pdf
Major Shareholding Notification Classification · 98% confidence The document is titled 'PERSBERICHT GEREGLEMENTEERDE INFORMATIE' (Regulated Information Press Release) and announces the receipt of a 'transparantiekennisgeving' (transparency notification) regarding a change in significant shareholding, specifically crossing the 5% threshold as mandated by Belgian law (Wet van 2 mei 2007). This content directly relates to notifications about changes in significant share ownership levels crossing predefined thresholds. This aligns perfectly with the definition for Major Shareholding Notification (MRQ). Although it is a press release, the core subject matter is the notification itself, not just the announcement of a report (RPA) or a general regulatory filing (RNS).
2017-09-21 Dutch
Genomic Health and Biocartis Announce Agreement to Develop an Idylla™ IVD Oncotype DX® Breast Cancer Test to Broaden Global Patient Access
Regulatory Filings Classification · 95% confidence The document is explicitly labeled as a "PRESS RELEASE" and announces a "Strategic Collaboration" between Genomic Health and Biocartis regarding the development and commercialization of a diagnostic test. It contains forward-looking statements and contact information typical of a corporate announcement. This type of announcement, which details a significant business event (a strategic partnership/agreement) but is not a formal regulatory financial report (like 10-K, IR, or ER), most closely aligns with a general corporate announcement. Since there is no specific category for 'Strategic Partnership Announcement,' and it is not a formal financial report, it falls best under the general regulatory/corporate announcement category, 'Regulatory Filings' (RNS), as a fallback for significant, non-standard disclosures, or potentially 'Capital/Financing Update' (CAP) if the deal involved significant upfront payments or royalties, but the primary nature is informational about a business deal. Given the options, RNS is the most appropriate general category for a press release detailing a strategic agreement that isn't a core financial filing or earnings release.
2017-09-13 English
Genomic Health en Biocartis kondigen overeenkomst aan voor ontwikkeling van een IdyllaTM IVD Oncotype DX® Borstkanker Test om wereldwijde toegang voor patiënten te verbreden
Regulatory Filings Classification · 95% confidence The document is a press release written in Dutch announcing a strategic agreement between Genomic Health and Biocartis regarding the development and commercialization of the Oncotype DX Breast Recurrence Score® test on the IdyllaTM platform. This announcement details a business partnership, financial considerations (upfront payment, future milestones, royalties), and future product rollout plans. This type of announcement, detailing a significant business transaction or strategic alliance, does not fit neatly into the specific financial reporting categories (like 10-K, ER, IR) or specific corporate actions (like DIV, SHA, DIRS). It is a general corporate announcement regarding business strategy and partnership. Given the options, the most appropriate general category for a significant, non-standard regulatory or financial announcement that doesn't fit elsewhere is 'Regulatory Filings' (RNS), which serves as a broad category for miscellaneous corporate disclosures, or potentially 'Capital/Financing Update' (CAP) if the focus was purely on the payment structure, but the core is the strategic deal. Since it is a formal press release announcing a major business development, RNS (Regulatory Filings/General Regulatory Announcement) is the best fit as a catch-all for significant, non-standard corporate news releases.
2017-09-13 Dutch
170905 H1 2017 Results Press Release ENG_FINAL.pdf
Interim / Quarterly Report Classification · 100% confidence The document is a press release titled 'Biocartis Announces H1 2017 Results'. It provides a comprehensive overview of the company's business highlights, financial performance (including revenue, operating expenses, and cash position), and strategic outlook for the first half of the fiscal year. It contains substantive financial data and management commentary, fitting the definition of an Interim/Quarterly Report (IR). H1 2017
2017-09-07 English
170905 H1 2017 Results Press Release NL_FINAL.pdf
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive financial report for the first half of 2017 (H1 2017) for Biocartis Group NV. It includes detailed financial highlights, operational results, management commentary, and references to IAS 34 'Interim Financial Reporting'. It is not a mere announcement of a report, but the report itself containing substantive financial data and analysis, fitting the definition of an Interim/Quarterly Report. H1 2017
2017-09-07 Dutch

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.